15 Jul 2015 05:18
Wed, 12th Dec 2018 09:21
Investec reiterated a 'buy' rating and price target of 647p for pharmaceuticals firm BTG after reappraising its key product Varithena. The bank said investors overreacted to concerns over BTG's earning profile, in particular the varicose vein treatment Varithena. "After interviewing physicians and
Read more